EG BioMed today announced a pivotal advancement in its global intellectual property portfolio. The company’s breakthrough technology for breast cancer monitoring has officially been granted patent certificates by the patent offices of Japan and South Korea, marking a significant achievement in EG BioMed’s ongoing commitment to delivering innovative diagnostic solutions to the international market.
Advancing Precision Oncology
The newly secured patents encompass EG BioMed’s proprietary core technology: Methods for Treatment Response, Recurrence and Prognosis Monitoring of Breast Cancer.
This core technology offers a systematic scientific approach to comprehensive breast cancer management. Utilizing advanced molecular diagnostics, the methodology provides critical clinical data support throughout various stages of the patient journey from monitoring patient response to specific treatments to the vigilant tracking of potential recurrence risks.
This patented technology has been licensed to YD Bio and implemented in the OkaiDx™ Breast Cancer Monitoring Blood Test, enabling non-invasive, blood-based monitoring using circulating tumor DNA (ctDNA).
Realizing a Vision for Health Through Science
Securing patents in Japan and South Korea two markets renowned for their rigorous standards in medical technology
validates both the scientific integrity and the clinical utility of our platform, the company stated. This milestone further strengthens the foundation of EG BioMed’s mission: to contribute to the health and well-being of humanity through the power of science.
Looking Ahead
As EG BioMed continues to expand its global biotechnology footprint, these patent grants reinforce our competitive edge in the field of precision medicine. We remain dedicated to transforming complex biological data into actionable clinical insights, ensuring that patients worldwide benefit from precise, timely, and data-driven monitoring tools.